Canaccord Genuity Reiterates Buy Rating, $100 PT on Watson Pharmaceuticals
December 31, 2012 at 12:07 PM EST
In a report published Monday, Canaccord Genuity reiterated its Buy rating and $100.00 price target on Watson Pharmaceuticals (NYSE: WPI ). Canaccord Genuity noted, “It was announced this morning that Mallinckrodt (subsidiary of Covidien) has received FDA approval for the 27, 36 and 54 mg dosage strengths of Concerta ER
